The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2010Generation and Characterization of iPS Neurons from PINK1- and Parkin-linked Parkinson's Disease
Objective/Rationale:
Recent reports have demonstrated that skin cells from patients with Parkinson’s disease can be reprogrammed into pluripotent stem cells (iPS) and subsequently differentiated into... -
MJFF Research Grant, 2010Probing the Function of SGK1 and its Relationship to LRRK2 and Parkinson’s Disease
Objective/Rationale:
Genetic testing of 3,500 Parkinson’s disease (PD) patients revealed that mutations in serum glucocorticoid-regulated kinase 1 (SGK1) gene reverts the risk of getting Parkinson’s... -
MJFF Research Grant, 2010Support for your Collaboration on Proof-of-concept clinical trial on the use of the 5-HT1A/1B Partial Agonist Eltoprazine for Treatment of L-DOPA-induced Dyskinesias. - Linked to Bjorklund CIA 2009
Objective/Rationale:
We have identified a new potential drug target for Parkinson's disease -- receptors located on the so-called serotonin neurons in the brain -- for alleviation of involuntary... -
MJFF Research Grant, 2010Generation of Phosphospecific LRRK2 Antibodies
Objective/Rationale:
LRRK2 (Leucine-Rich Repeat Kinase 2) is a protein thought to be involved in regulating signaling pathways in cells. Mutations in the gene for LRRK2 are associated with some... -
MJFF Research Grant, 2010Generation of PINK1 Antibodies
Objective/Rationale:
PINK1 (PTEN-Induced Kinase 1) is a protein involved in regulating signaling pathways in the energy “powerhouse” of cells, known as mitochondria. Mutations in the gene for PINK1 are... -
Target Validation, 2010Kynurenine 3-monooxygenase (KMO) as a Target to Develop Drugs to Block Progression of Parkinson's Disease
Objective/Rationale:
These studies will validate the enzyme kynurenine 3-monooxygenase (KMO) as a target to develop drugs to treat PD (PD). KMO is expressed in cells involved in inflammation, which is...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.